01
Jul 2020
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
17
Sep 2019
BenevolentAI announces $90 million investment from Temasek
BenevolentAI has raised $90 million from Temasek. The funding will be used to scale and develop the Benevolent Platform as well as further progress BenevolentAI drug programmes developed in-house and through collaborations.
04
Sep 2019
BenevolentAI announces agreement with leading healthcare company to leverage BenevolentAI’s technology platform
BenevolentAI has collaborated with Novartis Global Drug Development on an initial project in oncology, which will see the application of our AI and machine learning technology to stratify patients to more precisely target medicines.
04
Aug 2019
Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence
Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.
